Get the Stockscreener App
15.25
3.24%
0.43
Avadel Pharmaceuticals Plc stock is traded at $15.25, with a volume of 267.76K.
It is up +3.24% in the last 24 hours and up +36.24% over the past month.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
See More
Previous Close:
$14.82
Open:
$14.9
24h Volume:
267.76K
Relative Volume:
0.21
Market Cap:
$1.49B
Revenue:
$221.08M
Net Income/Loss:
$-2.92M
P/E Ratio:
305.00
EPS:
0.05
Net Cash Flow:
$5.89M
1W Performance:
+11.76%
1M Performance:
+36.24%
6M Performance:
+81.93%
1Y Performance:
-5.38%
1-Day Range:
$14.85
$15.39
1-Week Range:
$13.40
$15.39
52-Week Range:
$6.38
$16.66
Avadel Pharmaceuticals Plc Stock (AVDL) Company Profile
Name
Avadel Pharmaceuticals Plc
Sector
Phone
636-449-1830
Address
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, DUBLIN
Compare AVDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVDL
Avadel Pharmaceuticals Plc
|
15.30 | 1.31B | 221.08M | -2.92M | 5.89M | 0.05 |
|
ZTS
Zoetis Inc
|
157.27 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.47 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.865 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.89 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
313.24 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Avadel Pharmaceuticals Plc Stock (AVDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Resumed | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jun-12-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-05-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-05-24 | Reiterated | Needham | Buy |
| Mar-05-24 | Reiterated | Oppenheimer | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Nov-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-28-22 | Resumed | Craig Hallum | Buy |
| May-26-22 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jul-31-20 | Initiated | Oppenheimer | Outperform |
| Jul-21-20 | Initiated | SVB Leerink | Outperform |
| Jun-30-20 | Initiated | H.C. Wainwright | Buy |
| Apr-03-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Initiated | Stifel | Buy |
| Feb-26-20 | Initiated | Piper Sandler | Overweight |
| Jan-30-20 | Initiated | Craig Hallum | Buy |
| Jun-14-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-08-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
View All
Avadel Pharmaceuticals Plc Stock (AVDL) Latest News
Earnings call transcript: Avadel Pharmaceuticals beats Q2 2025 expectations - Investing.com
Avadel Pharmaceuticals plc Attempts Reversal From Key SupportPortfolio Value Summary & Reliable Entry Point Alerts - mustnews.co.kr
Are Options Traders Betting on a Big Move in Avadel Pharmaceuticals Stock? - Yahoo Finance
Can Avadel Pharmaceuticals plc Escape Recent Bear ChannelEarnings Recap Report & Free Weekly Watchlist of Top Performers - beatles.ru
Avadel Pharmaceuticals (NASDAQ:AVDL) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Avadel (AVDL) Q2 Revenue Jumps 64% - AOL.com
Avadel Pharmaceuticals Plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - 富途牛牛
Wall Street Analysts Predict a 37.25% Upside in Avadel (AVDL): Here's What You Should Know - Zacks Investment Research
Avadel Pharmaceuticals Plc (NASDAQ:AVDL) Has Found A Path To Profitability - 富途牛牛
Results: Avadel Pharmaceuticals plc Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Avadel Pharmaceuticals plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Yahoo Finance
Craig-Hallum Maintains Buy Rating for Avadel Pharmaceuticals with $18 Price Target - AInvest
Avadel Pharmaceuticals Q2 2025 Earnings Call Transcript: Forward-Looking Statements and Risks - AInvest
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q2 2025 Earnings Call Transcript - Insider Monkey
Avadel Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Avadel raises 2025 revenue guidance to $275M as LUMRYZ patient base grows 63% year-over-year - MSN
Avadel Pharmaceuticals shares fall 2.43% intraday after announcing inducement awards. - AInvest
Avadel Pharmaceuticals stock price target raised to $24 at H.C. Wainwright - Investing.com Nigeria
Avadel Pharmaceuticals: HC Wainwright Raises Buy Rating, PT to $24 - AInvest
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Avadel Pharmaceuticals PLC (AVDL) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Avadel Pharmaceuticals Raises 2025 Revenue Guidance to $275M Amid 63% YoY Growth in LUMRYZ Patient Base - AInvest
Avadel Pharmaceuticals Reports Strong Q2 Growth - TipRanks
Avadel: Q2 Earnings Snapshot - The Washington Post
Avadel Pharmaceuticals PLC reports results for the quarter ended June 30Earnings Summary - TradingView
AVADEL PHARMACEUTICALS PLC SEC 10-Q Report - TradingView
Avadel Pharma earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
Avadel Pharma Q2 revenue up 64%, raises 2025 guidance - MarketScreener
Earnings Flash (AVDL) Avadel Pharmaceuticals Posts Q2 EPS $0.10, vs. FactSet Est of $0.03 - MarketScreener
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results - TradingView
Avadel raises FY25 revenue guidance to $265-$275 mln after Q2 net rev. of $68.1 mln. - AInvest
Avadel Q2 rev up 64% to $68.1mln, raises FY25 guidance to $265-$275mln. - AInvest
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance - The Manila Times
Avadel Earnings: Revenue Soars 64%, Reports First Profit Since LUMRYZ Launch, Boosts 2025 Outlook - Stock Titan
Avadel Pharmaceuticals PLC expected to post earnings of 3 cents a shareEarnings Preview - TradingView
Avadel Pharmaceuticals plc Volume Confirms Breakout — Analysts BullishSwing Trading Plan With Smart Signals in Review - beatles.ru
What catalysts could drive Avadel Pharmaceuticals plc stock higher in 2025Discover undervalued opportunities early - Jammu Links News
What is the risk reward ratio of investing in Avadel Pharmaceuticals plc stockUnlock powerful trading tools for investors - Jammu Links News
What is the dividend policy of Avadel Pharmaceuticals plc stockSuperior investment outcomes - Jammu Links News
What analysts say about Avadel Pharmaceuticals plc stockUnprecedented growth rates - Jammu Links News
What is Avadel Pharmaceuticals plc company’s growth strategyBoost your returns with professional guidance - Jammu Links News
How many analysts rate Avadel Pharmaceuticals plc as a “Buy”Superior profit margins - Jammu Links News
How does Avadel Pharmaceuticals plc compare to its industry peersHigh-yield capital appreciation - Jammu Links News
Is Avadel Pharmaceuticals plc a good long term investmentFree Predictions - Jammu Links News
When is Avadel Pharmaceuticals plc stock expected to show significant growthOutperformance with explosive growth - Jammu Links News
How volatile is Avadel Pharmaceuticals plc stock compared to the marketCapitalize on emerging growth stocks - Jammu Links News
What are the latest earnings results for Avadel Pharmaceuticals plcInvest in stocks with strong fundamentals - Jammu Links News
A Piece Of The Puzzle Missing From Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 26% Share Price Climb - simplywall.st
Avadel Pharmaceuticals Plc Stock (AVDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avadel Pharmaceuticals Plc Stock (AVDL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thornton Peter J. | Director |
Jan 13 '25 |
Buy |
8.04 |
10,000 |
80,450 |
104,055 |
| Ende Eric J | Director |
Jan 13 '25 |
Buy |
7.84 |
30,000 |
235,218 |
208,900 |
| MCHUGH THOMAS S | Chief Financial Officer |
Dec 13 '24 |
Buy |
10.44 |
2,300 |
24,019 |
87,800 |
| MCHUGH THOMAS S | Chief Financial Officer |
Dec 11 '24 |
Buy |
10.49 |
5,000 |
52,432 |
85,500 |
| Divis Gregory J | Chief Executive Officer |
Dec 06 '24 |
Buy |
9.98 |
9,598 |
95,759 |
9,598 |
| Divis Gregory J | Chief Executive Officer |
Dec 09 '24 |
Buy |
9.82 |
402 |
3,948 |
10,000 |
| Glass Geoffrey Michael | Director |
Dec 10 '24 |
Buy |
9.84 |
20,279 |
199,641 |
75,904 |
| Palczuk Linda | Director |
Dec 06 '24 |
Buy |
10.19 |
3,000 |
30,568 |
66,400 |
0.46%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):